20/20 BioLabs Secures Exclusive License for PSA Velocity Algorithm to Boost OneTest Platform
20/20 BioLabs secured exclusive worldwide rights to a PSA velocity algorithm from the University of South Carolina that detects aggressive prostate tumors before PSA levels exceed 4 ng/mL. It will integrate into the OneTest platform and be offered as SaaS to clinical labs, expanding AI-driven test capabilities and revenue streams.
1. Licensing Agreement Details
The exclusive, worldwide licensing agreement grants 20/20 BioLabs commercialization rights to a patented PSA velocity algorithm developed at the University of South Carolina. This algorithm analyzes serial PSA measurements to identify rapidly growing prostate tumors before levels surpass 4 ng/mL.
2. Integration into OneTest Platform
20/20 BioLabs will integrate the algorithm into its OneTest blood-based multi-cancer early detection platform, enhancing its AI-driven analytics with longitudinal risk assessment for prostate cancer.
3. SaaS Offering to Clinical Labs
The company plans to offer the algorithm as a software-as-a-service license to clinical laboratories, opening a new recurring revenue stream and broadening its global market reach.
4. Strategic Growth Implications
By adding this longitudinal assessment tool, 20/20 BioLabs aims to strengthen its product differentiation, drive adoption of OneTest, and position itself for long-term growth in the early cancer detection market.